Ruyi Jinhuang Powder Veterinary Grade API (Model RJH-VAPI-2401) is supplied as a milled multi-herb powder for seven veterinary dosage-form routes: tablets, injectable solutions, capsules, oral powders, granules, premixes, and drinking-water solutions. The grade designation RJH-VAPI-2401 encodes the botanical formula RJH, the veterinary API segment, and the current process edition 2024-01. The material is controlled against two retention marker compounds, berberine hydrochloride and aloe-emodin, rather than a single isolated chemical entity. This release strategy is used because the API retains non-volatile extractive matter, micro-fiber, and a small amount of acid-insoluble ash from the botanical source; the full extractive profile is considered relevant to veterinary formulation performance.

Packaging comprises a 25 kg HDPE drum with double LDPE liners, net weight tolerance ±0.2 kg. Storage is specified at ≤25°C and ≤60% RH; under these conditions the manufacturer assigns a 24-month retest interval from date of manufacture. The product is not sterile and is not depyrogenated; it is intended as an API for further processing only. Compared with common food-grade or unstandardized crude powders, RJH-VAPI-2401 differs in particle size control, marker content, and elemental impurity documentation. The release specification requires not less than 95.0% passing a 75 µm sieve and marker assay of not less than 0.35% w/w berberine hydrochloride and 0.10% w/w aloe-emodin. Total ash is limited to ≤9.0%, acid-insoluble ash to ≤2.0%, and elemental impurities to Pb ≤5 ppm, Cd ≤2 ppm, As ≤3 ppm, and Hg ≤1 ppm by USP <232>/<233> methodology.

Differentiation from purified extract powders and single-chemical veterinary APIs is operational as well as compositional. A purified alkaloid fraction may offer better flowability but does not reproduce the co-occurring tannin and polysaccharide behavior encountered in oral and injectable products. RJH-VAPI-2401 therefore requires dosage-form-specific particle size reduction, endotoxin control, and pH management; these requirements are not present with a single-marker synthetic chemical API. In addition, the API is supplied with a chromatographic fingerprint for batch-to-batch consistency, rather than only a single assay value. This provides traceability in multi-herb supply chains but increases the analytical burden at incoming quality control.

What Limits Direct Compression Use of This Powder in Veterinary Tablets?

The powder is not a free-flowing direct-compression grade. In pilot-scale evaluation using a 45-station rotary tablet press, untreated API at compression force from 8 kN to 15 kN produced capping and lamination at press speeds above 35 rpm. Root-cause data from the same runs showed Hausner ratio 1.45–1.55 and Carr index 31–35%, both above the direct-compression usability threshold of Carr index ≤25% described in USP <1174>. The lignocellulosic fraction exhibits elastic recovery after compression, which reduces tensile strength at ejection.

Wet granulation is therefore the recommended processing route for tablet batches. In a production-scale train, the API is blended with lactose monohydrate and partly pregelatinized starch in a 600 L high-shear granulator at impeller 150 rpm and chopper 1800 rpm. Purified water is added to 9–12% w/w. The wet mass is screened through a 1.2 mm screen and dried in a fluid-bed dryer at inlet air 55–65°C to a final granule moisture of 2.5–4.0% w/w. Final compression on a 45-station rotary press at 60–80 rpm uses compression force 15–22 kN; ejection force is monitored and controlled below 1500 N. Under these conditions, 500 mg tablets achieve hardness 80–120 N and friability ≤0.8% by USP <1216>. Direct compression should be considered only if the API is co-processed with silicified microcrystalline cellulose and fumed silica; even then, blend flow must be confirmed by shear cell testing and ejection force signature on the actual production machine.

Hard capsule production with this API requires an intermediate granulation step unless a high-shear blended powder with glidant is accepted. On a production-scale tamping pin capsule filler running 60,000 capsules/h, direct powder fill of untreated API into size 1 hard gelatin capsules produced weight variation above 5.0% and frequent powder bridging, because the powder flow index remained below the acceptable mass-flow regime. Dry granulation on a roller compactor with roll force 18–25 kN/cm and screen size 0.8 mm, followed by blending with 0.5% w/w fumed silica and 1.0% w/w magnesium stearate, reduced weight variation to ≤2.0%. For oral powders and granules, the API is blended in a 2,000 kg ribbon mixer at 60% fill and 12 rpm for 10 min; a carrier of lactose monohydrate or corncob granules with particle size 150–300 µm is preferred. Final sachet filling uses volumetric auger fillers; fill weight variation is maintained at ±5.0% for 20 g sachets.

Particle Size, Moisture Sorption, and Blend Uniformity Parameters

Particle size distribution is measured by laser diffraction on a Malvern Mastersizer 3000 with dry dispersion at 2.0 bar. A typical batch shows D10 12 µm, D50 48 µm, and D90 97 µm. The milled API is packaged only after the D90 value remains ≤97 µm for three consecutive samples. Moisture sorption is evaluated by dynamic vapor sorption at 25°C; equilibrium moisture content is 7.2–8.4% w/w at 60% RH, rising to 11.0–12.5% w/w at 75% RH. Bulk handling above 65% RH is therefore restricted; drums should be closed within 30 min after sampling.

Blend uniformity in low-dose premixes is sensitive to API particle size. In a 500 kg double-cone blender at 60% fill and 14 rpm, a 1.0% active premix produced a blend uniformity acceptance value of 8 by USP <905> after 20 min when the API was milled to D90 ≤97 µm. The same formulation using unmilled API with D90 >180 µm produced an acceptance value above 15, indicating failure. Geometric dilution with 5.0 kg API added to 50 kg carrier before full-scale mixing is mandatory for active concentrations below 2.0%. The release specification and typical batch data are summarized in Table 1.

When Terminal Sterilization Is Required for Injectable Solutions

Injectable solutions prepared from RJH-VAPI-2401 require aqueous extraction rather than simple dissolution. The extraction liquor contains pectin-like polysaccharides, tannins, and calcium oxalate microcrystals that can foul sterilizing-grade membranes. At production scale, the clarified extract is first passed through a 0.45 µm PVDF prefilter and then a 0.22 µm PES membrane at a controlled feed pressure ≤1.5 bar. Two-stage filter capacity is typically 300–500 L/m² on 0.22 µm membrane before differential pressure increases by 0.5 bar, after which the membrane train is replaced. The acceptable pH window is 4.5–6.5. At pH above 8.0, accelerated stability at 40°C for 48 h produces visible particulate and a marker assay loss above 5.0%; at pH below 3.5, acid hydrolysis of glycosidic linkages increases free anthraquinone aglycones and changes the chromatographic fingerprint.

Terminal sterilization at 121°C for 15 min is acceptable only after thermal marker mapping on three consecutive production batches. If the assay loss exceeds 5.0%, aseptic filtration through 0.22 µm is substituted. Avoid combination with benzalkonium chloride in cationic preservative systems; turbidity has been observed due to anionic polyphenol interactions. Type I borosilicate glass vials with halogenobutyl closures are used because published sorption data for polycarbonate or PVC containers with this specific multi-herb extract is limited.

Premix production on farm-scale feed blending equipment requires the API to be diluted to a working concentration of 2.0–5.0% w/w in a non-hygroscopic carrier before final feed mixing. In a 1,500 kg twin-shaft paddle mixer at 20 rpm, a 10-min blend time after geometric dilution yields a coefficient of variation ≤5.0% by USP <905> stratified sampling at 10 points. The finished premix is packaged in aluminum foil-lined multi-wall bags with desiccant; moisture pickup under 25°C/60% RH remains below 0.8% w/w over 24 months. For drinking-water solutions, the formulator should use a buffered vehicle at pH 4.5–6.5 and a 0.2% w/w xanthan gum suspending agent; high-shear mixing at 1,500 rpm for 20 min produces a viscosity of 250–450 mPa·s and a 24-h sedimentation ratio not greater than 0.9. Hard water with calcium above 120 mg/L should be chelated or softened before use, because polyphenolic fractions form haze and sediment in the presence of divalent cations. Published data for this specific product in tropical zone IVb long-term storage is limited; local stability qualification is required before zone IVb distribution.